Understanding adaptive immune responses to SARS-CoV-2 is important for vaccine development efforts, interpreting disease pathogenesis, and calibration of future pandemic control measures. We have developed HLA class I and class II predicted peptides, collected into ‘Megapools’ (MP), to identify SARS-CoV-2–specific CD4+ and CD8+ T cells in coronavirus disease 2019 (COVID-19) convalescent patients. Importantly, we detected SARS-CoV-2 reactive CD4+ T cells in 40-60% unexposed individuals sampled before 2019, implicating preexisting cross-reactive T-cell memory. Using human blood samples derived pre-2019, we demonstrated a range of preexisting memory CD4+ T cells that are cross-reactive with comparable affinity to SARS-CoV-2 and HCoV-OC43, HCoV-229E, HCoV-NL63, or HCoV-HKU1. Thus, variegated T-cell memory to common cold coronaviruses may underlie at least some of the extensive heterogeneity observed in COVID-19 clinical and subclinical disease.